| Home |
|
AOAC Stakeholders Panel on Veterinary Drug Residues Comes to Consensus on Fitness-for-Purpose An expert review panel (ERP) is planned for early March at AOAC headquarters in Gaithersburg, Maryland, USA, to determine candidate method(s) for ractopamine, a veterinary drug, in animal tissues. Armed with a fitness-for-purpose statement developed by AOAC, with input from Elanco Animal Health, and from stakeholders who met in October, ractopamine will be the first in a series of veterinary drugs under review. Future ERPs will be convened for tylosin, monensin, and narasin. With ractopamine used worldwide, and with much of the current methodology decidedly out of date, a new AOAC Official MethodSM is needed for the analysis of ractopamine in animal tissues (swine and cattle) according to the some 50 key stakeholders from government, industry, academia, trade and contract research organizations, and animal drug manufacturers who met on October 2-3, 2008. To address specific analytical issues, working groups were formed to (1) consider the composition and make recommendations for the membership of the larger stakeholders group, with, in particular, a focus on ensuring balance (i.e., the number of members from industry, academia, governments, etc.) and international representation; (2) address the critical issue of applicable maximum residue limits established worldwide; (3) determine method performance criteria; and (4) address the need for confirmation of analyte identification, quality assurance, laboratory certification, etc. Coverage of the AOAC Stakeholders Panel on Veterinary Drug Residues is scheduled for the January/February issue of Inside Laboratory Management For more information, or if you would like to be part of the work of the Stakeholders Panel on Veterinary Drug R"sidues, contact Bob Rathb one, senior director, publications and method validation and evaluation at rathbone@aoac.org or Al Pohland, chief scientific officer, chemistry, at apohland@aoac.org.
|
